Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 1;11(5):2034–2047. doi: 10.7150/thno.51344

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Characterization of EVs from stage IV CRC patients. All CRC patient-derived EVs displayed similar shapes, size distributions, and EV-specific marker expression. (A) Representative particle size (relating to Patient 1) distribution analysis of plasma-derived EVs obtained by nanoparticle tracking analysis (NTA). (B) Expression analysis of EV marker proteins Tumor Susceptibility Gene-101 (TSG101) and tetraspanin proteins (CD63 and CD9) in plasma-derived EVs from patients or healthy donors. (C) Representative EV imaging (relating to Patient 1) by cryo-electron microscopy, scale bar: 100 nm. Additional images are shown in Supplementary Figure 1.